Skip to main content
Full access
Correction
Published Online: 19 July 2002

Erratum

In the the article “New Antipsychotic Boasts Better Side-Effect Profile” in the June 21 issue, the discovery and development of a new antipsychotic drug, aripiprazole, were attributed solely to Bristol-Myers Squibb Company (BMS). Aripiprazole was originally discovered by Otsuka Pharmaceutical Company Ltd. of Japan. Otsuka and BMS then codeveloped the drug and will promote the medication under the proposed brand name Abilitat, for the treatment of schizophrenia, pending FDA approval. ▪

Information & Authors

Information

Published In

History

Published online: 19 July 2002
Published in print: July 19, 2002

Authors

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share